Showing 2251-2260 of 3039 results for "".
- FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu Lens System in Patients with Cataractshttps://modernod.com/news/fda-grants-atia-vision-approval-to-begin-us-clinical-trial-of-omnivu-lens-system-in-patients-with-cataracts/2482811/Atia Vision has received Investigational Device Exemption (IDE) approval from the FDA to begin a traditional feasibility clinical study of its OmniVu Lens System. This novel IOL is designed to restore dynamic range of vision following catar
- Genentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DMEhttps://modernod.com/news/genentech-largest-real-world-studies-show-vabysmos-long-term-benefits-for-wet-amd-dme/2482798/Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet
- Ashvattha Therapeutics Presents Positive Phase 2 Results for Subcutaneous Migaldendranib in Retinal Vascular Diseasehttps://modernod.com/news/ashvattha-therapeutics-present-positive-phase-2-results-for-subcutaneous-migaldendranib-in-retinal-vascular-disease-at-arvo/2482795/Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib (MGB), a novel subcutaneously administered nanomedicine treatment for retinal vascular diseases. Updated results were presented in a poster session at the
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o
- Heidelberg Engineering Showcases Technologies to Enhance the Future of Imaging Technology at ARVOhttps://modernod.com/news/heidelberg-engineering-showcases-technologies-to-enhance-the-future-of-imaging-technology-at-arvo/2482771/Heidelberg Engineering announced a portfolio of innovations aimed at redefining image quality, clinical research, and patient care in ophthalmology at ARVO. According to Heidelberg, Chameleon Imaging Research Platform is des
- Medical Journals Cite “Harassment” After Increased Scrutiny from Justice Departmenthttps://modernod.com/news/medical-journals-cite-harassment-after-increased-scrutiny-from-justice-department/2482762/At least three major medical journals have reported receiving a letter from the U.S. Department of Justice (DOJ) that questioned their editorial practices and st
- MicroSurgical Technology (MST) to Discuss Advances in Vitrectomy Technology at ASCRShttps://modernod.com/news/microsurgical-technology-mst-to-discuss-advances-in-vitrectomy-technology-at-ascrs/2482749/MicroSurgical Technology (MST) announced it will share research during two presentations on the Vista 1-Step novel vitrectomy probe at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28. The
- BVI Medical Receives FDA 510(k) Clearance for the Leos Laser Endoscopy Ophthalmic Systemhttps://modernod.com/news/bvi-medical-announces-fda-510k-clearance-of-the-leos-laser-endoscopy-ophthalmic-system/2482743/BVI Medical has received 510(k) clearance from the FDA for its glaucoma surgical system, Leos (Laser Endoscopy Ophthalmic System). Leos introduces a novel, intuitive laser ECP procedure designed to integrate seamlessly into the surgical workflow. According to BVI, it
- Applications Being Accepted for the 2025 Ramin Tadayoni Awardhttps://modernod.com/news/applications-being-accepted-for-the-2025-ramin-tadayoni-award/2482740/Oculis, in collaboration with EURETINA, announced that applications are now being accepted for the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute
- Atsena Granted FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy to Treat X-Linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-designation-gene-therapy-to-treat-x-linked-retinoschisis/2482737/Atsena Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s novel spreading capsid, to